Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 03:04PM ET
1.49
Dollar change
+0.02
Percentage change
1.36
%
Index- P/E- EPS (ttm)-3.11 Insider Own0.84% Shs Outstand3.19M Perf Week-0.67%
Market Cap4.75M Forward P/E- EPS next Y-0.60 Insider Trans0.00% Shs Float3.16M Perf Month-3.87%
Income-9.29M PEG- EPS next Q-0.91 Inst Own0.77% Short Float0.64% Perf Quarter11.18%
Sales0.00M P/S- EPS this Y52.23% Inst Trans37.81% Short Ratio1.12 Perf Half Y-1.32%
Book/sh3.69 P/B0.40 EPS next Y60.00% ROA-55.51% Short Interest0.02M Perf Year-29.38%
Cash/sh3.27 P/C0.46 EPS next 5Y- ROE-59.63% 52W Range1.15 - 2.98 Perf YTD6.43%
Dividend Est.- P/FCF- EPS past 5Y-11.34% ROI-79.04% 52W High-50.00% Beta1.23
Dividend TTM- Quick Ratio8.51 Sales past 5Y0.00% Gross Margin- 52W Low29.57% ATR (14)0.09
Dividend Ex-Date- Current Ratio8.51 EPS Y/Y TTM12.28% Oper. Margin0.00% RSI (14)49.92 Volatility4.60% 5.93%
Employees6 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price40.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q17.58% Payout- Rel Volume0.98 Prev Close1.47
Sales Surprise- EPS Surprise-77.83% Sales Q/Q- EarningsMar 25 BMO Avg Volume18.07K Price1.49
SMA200.30% SMA500.49% SMA200-6.64% Trades Volume15,962 Change1.36%
Date Action Analyst Rating Change Price Target Change
Feb-12-21Initiated Ladenburg Thalmann Buy $7
Mar-25-24 01:53PM
08:00AM
Mar-12-24 09:15AM
Feb-15-24 09:00AM
Jan-23-24 08:30AM
08:30AM Loading…
Jan-08-24 08:30AM
Dec-05-23 08:30AM
Nov-30-23 09:00AM
Nov-13-23 08:00AM
Nov-09-23 09:00AM
Nov-02-23 08:30AM
Oct-04-23 08:30AM
Sep-13-23 08:30AM
Sep-07-23 08:00AM
Sep-06-23 09:00AM
09:00AM Loading…
Sep-05-23 09:00AM
Aug-10-23 08:00AM
Jul-19-23 09:00AM
Jul-10-23 08:30AM
Jun-28-23 08:30AM
Jun-27-23 08:30AM
Jun-26-23 08:30AM
Jun-07-23 08:30AM
May-11-23 08:00AM
Apr-25-23 08:30AM
Mar-31-23 08:00AM
Feb-15-23 08:30AM
Feb-02-23 09:00AM
Jan-26-23 08:30AM
Nov-08-22 08:00AM
08:30AM Loading…
Oct-18-22 08:30AM
Sep-22-22 09:00AM
Sep-07-22 08:30AM
Aug-16-22 09:00AM
Aug-09-22 08:10AM
Jul-19-22 09:07AM
Jun-27-22 08:30AM
Jun-24-22 08:30AM
Jun-01-22 08:30AM
May-16-22 01:20PM
08:55AM
May-13-22 08:30AM
May-12-22 08:30AM
Apr-26-22 07:33AM
Apr-25-22 07:30AM
Apr-13-22 08:30AM
Mar-28-22 09:25AM
Mar-22-22 09:00AM
Mar-21-22 08:30AM
Mar-02-22 08:30AM
Jan-12-22 08:30AM
Jan-11-22 08:30AM
Jan-10-22 09:00AM
Jan-04-22 01:38PM
Nov-29-21 08:30AM
Nov-11-21 08:30AM
Nov-02-21 07:33AM
Sep-08-21 08:30AM
Aug-11-21 04:18PM
Aug-04-21 08:30AM
Jul-21-21 08:30AM
Jul-12-21 08:30AM
Jul-07-21 08:30AM
Jun-22-21 08:00AM
Jun-02-21 08:30AM
May-06-21 07:00AM
May-04-21 08:00AM
Apr-20-21 02:02AM
Apr-13-21 08:30AM
Apr-12-21 08:30AM
Mar-19-21 10:00AM
Mar-11-21 07:10AM
Mar-09-21 08:30AM
Mar-02-21 08:30AM
Feb-17-21 08:30AM
Feb-16-21 08:30AM
Feb-12-21 10:56AM
Feb-08-21 08:30AM
Feb-02-21 08:30AM
Jan-29-21 04:05PM
Jan-14-21 08:30AM
Jan-05-21 08:30AM
Dec-09-20 08:30AM
Dec-08-20 08:30AM
Dec-02-20 08:30AM
Nov-23-20 08:30AM
Nov-16-20 08:30AM
Nov-11-20 08:30AM
Nov-04-20 08:00AM
Nov-02-20 05:48AM
Oct-21-20 08:30AM
Oct-14-20 04:05PM
Oct-09-20 08:30AM
Sep-29-20 08:00AM
Sep-11-20 09:00AM
Sep-10-20 09:15AM
Aug-31-20 06:12PM
Aug-26-20 09:30AM
Aug-05-20 11:04AM
Jul-14-20 09:25AM
Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.